Identifying biomarkers to predict immune-checkpoint therapy response-is it a reality or a distant dream?

On combining TMB with PD-L1 and studying the DCB, intermediate (1–50%) and high PD-L1 (>50%) with TMB did show a marginally significant improvement compared to low PD-L1 (<1%) and high TMB, despite the small sample size.

also in 26,082 other papers